Home / Conferences / Terrapinn World Biosimilar Congress 2017

Terrapinn World Biosimilar Congress 2017 Posted 25/08/2017

World Biosimilar Congress 2017
31 October – 1 November 2017
Basel, Switzerland

A critical industry gathering for biosimilar experts worldwide, the World Biosimilar Congress will bring industry and thought-leading speakers from across the globe together to network and discuss the key issues on biosimilar drug development, commercialization, market access and healthcare uptake.

Over 60 biosimilar experts will share their knowledge and we will be hosting over 300 biosimilar attendees from pharma, biotech, clinicians and health care.

Key topics include:

  • Market access strategies, opportunities and commercial challenges
  • Biosimilar and Biobetter development
  • Physician Education, Uptake & Market Access Strategies
  • Development, Manufacturing & Pharmacovigilance

Key speakers include:

  • Adam Levysohn, Head of Global Market Access Biogen Biosimilars Business Unit, Biogen
  • Benedicte Lunddahl, Section Leader, Head of Pharmacovigilance, Danish Medicines Agency
  • Caroline Boulliat, Biosimilar Business Unit Head, Amgen Europe GmbH
  • Elena Wolff-Holz, Chair, Biosimilar Medicinal Products Working Party (BMWP)
  • Erin Federman, Global Director – Team Lead, Immunology Biosimilars, Boehringer Ingelheim
  • Francois Xavier Frapaise, MD, CMO, Merck Biosimilars